INTRODUCTION
cancers, cognitive impairment
CANCERS
Cancer‐related cognitive impairment (CRCI) is a common and consequential condition described in many cancers and following a myriad of cancer‐directed therapies.Pharmacotherapies for CRCI present potential advantages over behavioral interventions, including targeting precise mechanisms, minimizing patient time investment, and requiring few facility resources. However, there have been <10 randomized controlled trials (RCTs) of medications for CRCI and the only agents that have been studied for CRCI prevention during chemotherapy–Ginkgo biloba, erythropoietin, and methylphenidate–have not been effective and/or presented acceptability and safety concerns.Memantine, an 